


Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		ocket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
		Applicant Donna T. Ward, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date November 21, 2003	Group <i>1635</i> Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Andrew, A.S. et al., "Nickel requires hypoxia-inducible factor-1 α , not redox signaling, to induce plasminogen activator inhibitor-1," <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> , 2001, 281, L607-L615	
	2	Caniggia, I. et al., "Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGF β 3," <i>J. Clin. Investigation</i> , 2000, 105(5), 577-587	
	3	Caniggia, I. et al., "Oxygen and Placental Development During the First Trimester: Implications for the Pathophysiology of Pre-eclampsia," <i>Placenta</i> , 2000, 21 Suppl. A, 14, S25-S30	
	4	Drutel, G. et al., "Two splice variants of the hypoxia-inducible factor HIF-1 α as potential dimerization partners of ARNT2 in neurons," <i>European J. Neurosci.</i> , 2000, 12, 3701-3708	
	5	Furuta, G.T. et al., "Hypoxia-inducible Factor 1-dependent Induction of Intestinal Trefoil Factor Protects Barrier Function during Hypoxia," <i>J. Exp. Med.</i> , 2001, 193(9), 1027-1034	
	6	Huang, L.E., et al., "Regulation of hypoxia-inducible factor 1 α is mediated by an O ₂ -dependent degradation domain via the ubiquitin-proteasome pathway," <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95, 7987-7992	
	7	Iyer, N.V. et al., "Cellular and developmental control of O ₂ homeostasis by hypoxia-inducible factor 1 α ," <i>Genes & Development</i> , 1998, 12, 149-162	
	8	Kakinuma, Y. et al., "Novel Molecular Mechanism of Increased Myocardial Endothelin-1 Expression in the Failing Heart Involving the Transcriptional Factor Hypoxia-Inducible Factor-1 α Induced for Impaired Myocardial Energy Metabolism," <i>Circulation</i> , 2001, 103, 2387-2394	
	9	Maxwell et al., "Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation," <i>Exp. Nephrol.</i> , 2001, 9, 235-240	
	10	Minchenko, A. et al., "Hypoxia-inducible factor-1 (HIF-1) mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene: its possible role in the Warburg effect," <i>J. Biol. Chem.</i> , 2001, 276, 21 pages	
EXAMINER 		DATE CONSIDERED <i>6/23/06</i>	



<p>Form PTO-1449 Modified</p> <p>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce Patent and Trademark Office</p>	Docket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
	<p>Applicant Donna T. Ward, et al.</p>	
	Filing Date November 21, 2003	Group 1635 Not Yet Assigned
	Confirmation No. Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

93	11	Naravula, S. et al., "Hypoxia-Inducible Factor 1-Mediated Inhibition of Peroxisome Proliferator-Activated Receptor α Expression During Hypoxia," <i>J. Immunol.</i> , 2001, 166, 7543-7548
	12	Ravi, R. et al., "Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α ," <i>Genes & Development</i> , 2000, 14, 43-44
	13	Ryan, H.E. et al., "HIF-1 α is required for solid tumor formation and embryonic vascularization," <i>EMBO J.</i> , 1998, 17(11), 3005-3015
	14	Semenza, G.L., "HIF-1 and human disease: one highly involved factor," <i>Genes & Development</i> , 2000, 14, 1983-1991
	15	Semenza, G.L., "Hypoxia-Inducible Factor 1: Control of Oxygen Homeostasis in Health and Disease," <i>Pediatr. Res.</i> , 2001, 49(5), 614-617
	16	Sun, X. et al., "Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy," <i>Gene Therapy</i> , 2001, 8, 638-645
.	17	Sutter, C.H. et al., "Hypoxia-inducible factor 1 α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations," <i>Proc. Natl. Acad. Sci. USA</i> , 2000, 97(9), 4748-4753
	18	Thrash-Bingham, C.A. et al., "aHIF: a Natural Antisense Transcript Overexpressed in Human Renal Cancer and During Hypoxia," <i>J. Natl. Cancer Inst.</i> , 1999, 91(2), 143-151
	19	Wang, G.L. et al., "Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O ₂ tension," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5510-5514
↓	20	Wang, G.L. et al., "Purification and Characterization of Hypoxia-inducible Factor 1," <i>J. Biol. Chem.</i> , 1995, 270(3), 1230-1237

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>6/23/06</i>
-----------------	--------------------	------------------------	----------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
		Applicant Donna T. Ward, et al.	
		Filing Date November 21, 2003	Group Not Yet Assigned 1635
		Confirmation No. Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

21	Yu, A.Y. et al., "Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 α ," <i>J. Clin. Investigation</i> , 1999, 103(5), 691-696
22	Zagzag, D. et al., "Expression of Hypoxia-Inducible Factor 1 α in Brain Tumors," <i>Cancer</i> , 2000, 88(11), 2606-2618
23	Cockman, M.E. et al., "Hypoxia Inducible Factor- α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein," <i>J. Biol. Chem.</i> , 2000, 275(33), 25733-25741
24	Conrad, P.W. et al., "The molecular basis of O ₂ -sensing and hypoxia tolerance in pheochromocytoma cells," <i>Comparative Biochem. Physiol.</i> , 2001, Part B, 128, 187-204
25	Conrad, W.P. et al., "EPAS1 trans-Activation during Hypoxia Requires p42/p44 MAPK," <i>J. Biol. Chem.</i> , 1999, 274(47), 33709-33713
26	Ema, M. et al., "A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 4273-4278
27	Favier, J. et al., "Angiogenesis and Vascular Architecture in Pheochromocytomas," <i>Am. J. Pathology</i> , 2002, 161(4), 1235-1246
28	Flamme, I. et al., "Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2 α ," <i>Am. J. Pathology</i> , 1998, 153(1), 25-29
29	Flamme, I. et al., "HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels," <i>Mechan. Develop.</i> , 1997, 63, 51-60
30	Giatromanolaki, A. et al., "Relation of hypoxia inducible factor 1 α and 2 α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival," <i>British J. Cancer</i> , 2001, 85(6), 881-890

EXAMINER	DATE CONSIDERED
----------	-----------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
	Applicant Donna T. Ward, et al.	
	Filing Date November 21, 2003	Group Not Yet Assigned <i>1635</i>
	Confirmation No. Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

31	Giatromanolaki, A. et al., "Hypoxia inducible factor 1 α and 2 α overexpression in inflammatory bowel disease," <i>J. Clin. Pathol.</i> , 2003, 56, 209-213
32	Harris, A.L., "Hypoxia – A Key Regulatory Factor in Tumour Growth," <i>Nature Reviews</i> , 2002, 2, 38-47
33	Hirsila, M. et al., "Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor," <i>J. Biol. Chem.</i> , 2003, 278(33), 30772-30780
34	Hogenesch, J.B. et al., "Characterization of a Subset of the Basic-Helix-Loop-Helix-PAS Superfamily That Interacts with Components of the Dioxin Signaling Pathway," <i>J. Biol. Chem.</i> , 1997, 272(13), 8581-8593
35	Koukourakis, M.I. et al., "Hypoxia-Inducible Factor (HIF1A and HIF2A), Angiogenesis, and Chemoradiotherapy Outcome of Squamous Cell Head-and-Neck Cancer," <i>Int. J. Radiation Oncology Biol. Phys.</i> , 2002, 53(5), 1192-1202
36	Leek, R.D. et al., "Relation of Hypoxia-inducible Factor-2 α (HIF-2 α) Expression in Tumor-infiltrative Macrophages to Tumor Angiogenesis and the Oxidative Thymidine Phosphorylase Pathway in Human Breast Cancer," <i>Cancer Res.</i> , 2002, 62, 1326-1329
37	Liang, Y et al., "Activation of Vascular Endothelial Growth Factor A Transcription in Tumorigenic Glioblastoma Cell Lines by an Enhancer with Cell Type-specific DNase I Accessibility," <i>J. Biol. Chem.</i> , 2002, 277(22), 20087-20094
38	Liu, M.Y., "Up-Regulation of Hypoxia-inducible Factor 2 α in Renal Cell Carcinoma Associated with Loss of Tsc-2 Tumor Suppressor Gene," <i>Cancer Res.</i> , 2003, 63, 2675-2680
39	Maemura, K. et al., "Generation of a Dominant-negative Mutant of Endothelial PAS Domain Protein 1 by Deletion of a Potent C-terminal Transactivation Domain," <i>J. Biol. Chem.</i> , 1999, 274(44), 31565-31570
40	Maxwell, P.H., "Activation of the HIF pathway in cancer," <i>Curr. Opin. Genetics & Develop.</i> , 2001, 11, 293-299
41	Maxwell, P.H., "The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis," <i>Nature</i> , 1999, 399, 271-275

EXAMINER

DATE CONSIDERED



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
		Applicant Donna T. Ward, et al.	
		Filing Date November 21, 2003	Group Not Yet Assigned <i>1635</i>
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	42	Ohh, M. et al., "Ubiquitination of hypoxia-inducible factor requires direct binding to the β -domain of the von Hippel-Lindau protein," <i>Nature Cell Biology</i> , 2000, 2, 423-427	
	43	Pugh, C.W. et al., "The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis," <i>Seminars in Cancer Biol.</i> , 2003, 13, 83-89	
	44	Rajakumar, A. et al., "Expression, Ontogeny, and Regulation of Hypoxia-Inducible Transcription Factors in the Human Placenta," <i>Biol. Reproduction</i> , 2000, 63, 559-569	
	45	Rajakumar, A. et al., "Selective Overexpression of the Hypoxia-Inducible Transcription Factor, HIF-2 α , in Placentas from Women with Preeclampsia," <i>Biol. Reproduction</i> , 2001, 64, 499-506	
	46	Safran, M. et al., "HIF hydroxylation and the mammalian oxygen-sensing pathway," <i>J. Clin. Investigation</i> , 2003, 111(6), 779-783	
	47	Sato, M. et al., "Inducible Expression of Endothelial PAS Domain Protein-1 by Hypoxia in Human Lung Adenocarcinoma A549 Cells: Role of Src Family Kinases-dependent Pathway," <i>Am. J. Respir. Cell Mol. Biol.</i> , 2002, 26, 127-134	
	48	Semenza, G.L., "Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology," <i>Trends in Mol. Med.</i> , 2001, 7(8), 345-350	
	49	Sowter, H.M. et al., "Predominant Role of Hypoxia-Inducible Transcription Factor (Hif)-1 α versus Hif-2 α in Regulation of the Transcriptional Response to Hypoxia," <i>Cancer Res</i> , 2003, 63, 6130-6134	
	50	Talks, K.L. et al., "The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1 α and HIF-2 α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages," <i>Am. J. Pathology</i> , 2000, 157(2), 411-421	
	51	Tanaka, T. et al., "Endothelial PAS Domain Protein 1 (EPAS1) Induces Adrenomedullin Gene Expression in Cardiac Myocytes: Role of EPAS1 in an Inflammatory Response in Cardiac Myocytes," <i>J. Mol. Cell Cardiol.</i> , 2002, 34, 739-748	
EXAMINER 		DATE CONSIDERED 	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
	Applicant Donna T. Ward, et al.	
	Filing Date November 21, 2003	Group Not Yet Assigned 1635
	Confirmation No. Not Yet Assigned	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

52	Tian, H. et al., "Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells," <i>Genes & Development</i> , 1997, 11, 72-82
53	Tian, H. et al., "The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development," <i>Genes & Development</i> , 1998, 12, 3320-3324
54	Wiesener, M.S. et al., "Induction of Endothelial PAS Domain Protein-1 by Hypoxia: Characterization and Comparison with Hypoxia-Inducible Factor-1 α ," <i>Blood</i> , 1998, 92(7), 2260-2268
55	Xia, G. et al., "Regulation of Vascular Endothelial Growth Factor Transcription by Endothelial PAS Domain Protein 1 (EPAS1) and Possible Involvement of EPAS1 in the Angiogenesis of Renal Cell Carcinoma," <i>Cancer</i> , 2001, 91(8), 1429-1436
56	Xia, G. et al., "Positive Expression of HIF-2 α /EPAS1 in Invasive Bladder Cancer," <i>Urology</i> , 2002, 5, 774-778

EXAMINER**DATE CONSIDERED**

6/23/06



Sheet 7 of 7

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. ISPT-1010/ PTS-0070.P1	Application No. 10/719,370
		Applicant Donna T. Ward, et al.	
		Filing Date November 21, 2003	Group <u>Not Yet Assigned</u> <i>X635</i>
		Confirmation No. Not Yet Assigned	


U. S. PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Name	Class	Subclass
<i>JJ</i>	57 5,882,914	03/16/99	Semenza	435	252.3
<i>JJ</i>	58 5,695,963	12/09/97	McKnight et al.	435	69.1
	59 6,395,548 B1	05/28/02	Lee et al.	435	455
	60 6,432,927 B1	08/13/02	Gregory et al.	514	44
<i>JJ</i>	61 2003/0045686 A1	03/06/03	Kaelin, Jr. et al.	530	350

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation	
				YES	NO
<i>JJ</i>	62 WO 00/09657	02/24/00	PCT		
<i>JJ</i>	63 WO 01/62965 A2	08/30/01	PCT		
	64 WO 02/34291 A2	05/02/02	PCT		
	65 WO 02/068466 A2	09/06/02	PCT		
	66 WO 02/086497 A2	10/31/02	PCT		
<i>JJ</i>	67 WO 02/094862 A2	11/28/02	PCT		

EXAMINER *JJ* **DATE CONSIDERED** *6-23-06*



AUG 24 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

<i>Complete if Known</i>	
<i>Application Number</i>	10/719,370
<i>Filing Date</i>	11/21/2003
<i>First Named Inventor</i>	Donna T. Ward
<i>Art Unit</i>	1623 1635
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	PTS-0070US.P1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature


Date
Considered

6-23-06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Applicant's unique citation designation number (optional).³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

WIPO Standard ST. 18, if possible. "Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Form PTO-1449 Modified	Docket No. ISPT-1010 (PTS-0070US.P1)	Application No. 10/719,370
<p>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce Patent and Trademark Office</p>	<p>Applicant Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson and Susan M. Freier</p>	
	Filing Date November 21, 2003	Group 1623 <i>1635</i>
	Confirmation No. 3593	

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER

DATE CONSIDERED

6-23-06

Form PTO-1449 Modified	Docket No. ISPT-1010 (PTS-0070US.P1)	Application No. 10/719,370
<p>List of Patent and Publications Cited by Applicant (Use several sheets if necessary)</p> <p>U.S. Department of Commerce Patent and Trademark Office</p>	<p>Applicant Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson and Susan M. Freier</p>	
	Filing Date November 21, 2003	Group 1623 <i>1635</i>
	Confirmation No. 3593	

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Translation	
				YES	NO
JZ	1 WO 03/085110 A2	10/16/03	PCT		
EXAMINER <i>JZ</i>		DATE CONSIDERED <i>6-23-06</i>			

EXAMINER

DATE CONSIDERED

6-23-06

PTO:SB:383 (03-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

<i>Complete If Known</i>	
<i>Application Number</i>	10/719,370
<i>Filing Date</i>	November 21, 2003
<i>First Named Inventor</i>	Donna T. Ward
<i>Art Unit</i>	1625 1635
<i>Examiner Name</i>	Not Yet Assigned
<i>Attorney Docket Number</i>	PTS-0070US.P1 (ISPT-1010)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner
Signature

Date Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹ Applicant's unique citation designation number (optional).** **² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** **⁵ Kind of document by the appropriate symbol/s as indicated on the document under WIPO Standard ST. 16 if possible.** **⁶ Applicant is to place a check mark here if English language Translation is attached.**

WIPO Standard ST. 16 if possible." Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.